ARCT News and Press, Arcturus Therapeutics Ltd. From 01/31/24

2024-01-31 17:20:05 ET Summary Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 bill...

2024-01-27 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster PR Newswire Study conducted by Meiji Seika Pharma in Japan Dat...

2023-12-15 17:03:39 ET Gainers: Loop Industries ( LOOP ) +6% . Cognyte Software  ( CGNT ) +5% . Generation  ( GBIO ) +5% . Northern Technologies International Corporation ( NTIC ) +5% . Arcturus Therapeutics Holdings ( ARCT ...

2023-12-13 13:48:55 ET More on Arcturus Therapeutics From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey Arcturus: COVID Vaccine Approval Shots In Japan And Europe Key To Unlocking Upside Arcturus Therapeutics Holdings Inc. (ARCT) Q3 20...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...

2023-11-28 14:14:56 ET More on Arcturus, CSL, etc. CSL Limited: Positive Capital Return And Earnings Growth Expectations From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey Arcturus: COVID Vaccine Approval Shots In Japan And Europe Key ...

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults PR Newswire Exclusive Partner in Japan , Meiji Seika Pharma advances regulatory approval ...

Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's promise to develop and deliver innovations when there is a public health need First ...

2023-11-27 13:13:29 ET U.S. President Joe Biden plans to invoke the Defense Production Act of 1950 to build up domestic production of essential drugs, as one of the many actions announced during the first meeting of his new supply chain resilience council. The Cold War-era federal l...